Insmed Stock News

Equities analysts predict that Insmed Incorporated (NASDAQ:INSM) will post earnings of ($0.89) per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Insmeds earnings. The highest EPS estimate is ($0.79) and the lowest is ($1.00). Insmed posted earnings per share of ($1.00) during the same quarter last year, which []

JPMorgan Chase & Co. began coverage on shares of Insmed (NASDAQ:INSM) in a report released on Monday, Price Targets.com reports. The brokerage issued an overweight rating and a $45.00 price target on the biopharmaceutical companys stock. INSM has been the subject of a number of other research reports. HC Wainwright restated a buy rating and []

Brokerages expect that Insmed Incorporated (NASDAQ:INSM) will report sales of $51.37 million for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Insmeds earnings, with the lowest sales estimate coming in at $49.14 million and the highest estimate coming in at $53.77 million. Insmed posted sales of $41.42 million during the [] The post Zacks: Brokerages Anticipate Insmed Incorporated (NASDAQ:INSM) Will Post Quarterly Sales of $51.37 Million appeared first on ETF Daily News .

Shares of Insmed Incorporated (NASDAQ:INSM) have earned an average rating of Buy from the seven analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price target among analysts that have issued []

Zacks Investment Research upgraded shares of Insmed (NASDAQ:INSM) from a sell rating to a hold rating in a research report sent to investors on Tuesday, Zacks.com reports. According to Zacks, Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient []

Shares of Insmed Incorporated (NASDAQ:INSM) have been given an average recommendation of Buy by the seven analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that []

Scout Investments Inc. cut its holdings in Insmed Incorporated (NASDAQ:INSM) by 1.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 331,865 shares of the biopharmaceutical companys stock after selling 4,560 shares during the period. Scout Investments Inc.s holdings in Insmed were worth $9,140,000 as of []

Equities research analysts expect that Insmed Incorporated (NASDAQ:INSM) will post $51.37 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Insmed’s earnings, with the lowest sales estimate coming in at $49.14 million and the highest estimate coming in at $53.77 million. Insmed reported sales of $41.42 million […]

Insmed Incorporated (NASDAQ:INSM) was the target of a significant decline in short interest in October. As of October 29th, there was short interest totalling 7,460,000 shares, a decline of 18.7% from the October 14th total of 9,180,000 shares. Based on an average daily volume of 808,100 shares, the days-to-cover ratio is currently 9.2 days. Several []

Equities research analysts forecast that Insmed Incorporated (NASDAQ:INSM) will report earnings of ($0.88) per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Insmeds earnings. The highest EPS estimate is ($0.79) and the lowest is ($1.00). Insmed posted earnings of ($1.00) per share during the same quarter last year, []

Wall Street brokerages expect Insmed Incorporated (NASDAQ:INSM) to post $53.39 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Insmeds earnings, with the highest sales estimate coming in at $58.63 million and the lowest estimate coming in at $49.14 million. Insmed reported sales of $41.42 million in the []

Insmed Incorporated's (INSM) CEO Will Lewis on Q3 2021 Results - Earnings Call Transcript

The shares of Insmed Incorporated (NASDAQ: INSM) have received a $60 price target from Cantor Fitzgerald. These are the details.

Insmed Inc. (INSM) CEO Will Lewis on Q2 2021 Results - Earnings Call Transcript

Insmed (INSM) has been struggling lately, but the selling pressure may be coming to an end soon.